The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use DOI Creative Commons
Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli

и другие.

Addiction, Год журнала: 2021, Номер 117(6), С. 1510 - 1517

Опубликована: Сен. 30, 2021

Abstract Background The lack of an agreed international minimum approach to measuring cannabis use hinders the integration multidisciplinary evidence on psychosocial, neurocognitive, clinical and public health consequences use. Methods A group 25 expert researchers convened discuss a framework for standards measure globally in diverse settings. Results expert‐based consensus upon three‐layered hierarchical framework. Each layer—universal measures, detailed self‐report biological measures—reflected different research priorities standards, costs ease implementation. Additional work is needed develop valid precise assessments. Conclusions Consistent proposed across research, health, practice medical settings would facilitate harmonisation consumption, related harms approaches their mitigation.

Язык: Английский

New trends in cannabis potency in USA and Europe during the last decade (2008–2017) DOI
Suman Chandra, Mohamed M. Radwan,

Chandrani G. Majumdar

и другие.

European Archives of Psychiatry and Clinical Neuroscience, Год журнала: 2019, Номер 269(1), С. 5 - 15

Опубликована: Янв. 22, 2019

Язык: Английский

Процитировано

412

Cannabis use and cannabis use disorder DOI
Jason P. Connor, Daniel Stjepanović, Bernard Le Foll

и другие.

Nature Reviews Disease Primers, Год журнала: 2021, Номер 7(1)

Опубликована: Фев. 25, 2021

Язык: Английский

Процитировано

310

Public health implications of legalising the production and sale of cannabis for medicinal and recreational use DOI
Wayne Hall, Daniel Stjepanović, Jonathan P. Caulkins

и другие.

The Lancet, Год журнала: 2019, Номер 394(10208), С. 1580 - 1590

Опубликована: Окт. 1, 2019

Язык: Английский

Процитировано

291

Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis DOI Creative Commons
Tom P. Freeman, Sam Craft, Jack Wilson

и другие.

Addiction, Год журнала: 2020, Номер 116(5), С. 1000 - 1010

Опубликована: Ноя. 7, 2020

Abstract Background and aims Cannabis products with high delta‐9‐tetrahydrocannabinol (THC) concentrations carry an increased risk of addiction mental health disorders, while it has been suggested that cannabidiol (CBD) may moderate the effects THC. This study aimed to systematically review meta‐analyse changes in THC CBD cannabis over time (PROSPERO registration: CRD42019130055). Design Embase, MEDLINE® Epub Ahead Print, In‐Process Other Non‐Indexed Citations Daily, Global Health, PsycINFO Scopus were searched from inception 27/03/2019 for observational studies reporting mean and/or concentration at least three annual points. Searches extraction conducted by two independent reviewers. Random meta‐regression models estimated each product within study; these estimates pooled across random models. Results We identified 12 eligible USA, UK, Netherlands, France, Denmark, Italy New Zealand. For all herbal cannabis, 0.29% year (95% CI: 0.11, 0.47), P < 0.001 based on 66 747 samples eight studies, 1970–2017. resin, 0.57% 0.10, 1.03), = 0.017 17 371 1975–2017. There was no evidence [−0.01% −0.02, 0.01), 0.280; 49 434 five 1995–2017] or resin [0.03% −0.11, 0.18), 0.651; 11 382 six 1992–2017]. Risk bias low apart non‐random sampling most studies. substantial heterogeneity. Conclusions Concentrations international markets 1970 2017 remained stable. Increases greater than cannabis. Rising attributable market share high‐THC sinsemilla relative low‐THC traditional

Язык: Английский

Процитировано

255

Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations DOI
Rosanna Smart, Rosalie Liccardo Pacula

The American Journal of Drug and Alcohol Abuse, Год журнала: 2019, Номер 45(6), С. 644 - 663

Опубликована: Окт. 11, 2019

Background: The past decade has seen unprecedented shifts in the cannabis policy environment, and public health impacts of these changes will hinge on how they affect patterns use harms associated with other substances.Objectives: To review existing research state substance use, emphasizing studies using methods for causal inference highlighting gaps our understanding evolving markets.Methods: Narrative quasi-experimental medical laws (MCLs) recreational (RCLs) disorders, as well or from alcohol, opioids, tobacco.Results: Research suggests MCLs increase adult but not adolescent provisions less regulated supply may disorders. These reduce some opioid-related harms, while their alcohol tobacco remain uncertain. RCLs is just emerging, findings suggest little impact prevalence potential increases college student unknown effects use.Conclusions: influence advanced importance heterogeneity policies, populations, market dynamics, relate to often ignore factors. Understanding requires greater attention differences short- versus long-term laws, nuances policies consumption, careful consideration appropriate control groups.

Язык: Английский

Процитировано

248

Assessing the public health impacts of legalizing recreational cannabis use: the US experience DOI Open Access
Wayne Hall, Michael T. Lynskey

World Psychiatry, Год журнала: 2020, Номер 19(2), С. 179 - 186

Опубликована: Май 11, 2020

The sale of cannabis for adult recreational use has been made legal in nine US states since 2012, and nationally Uruguay 2013 Canada 2018. We review research on the effects legalization among adults adolescents cannabis-related harms; impact legalizing price, availability, potency use; regulatory policies that may increase or limit adverse legalization. substantially reduced price cannabis, increased its potency, more available to users. It appears have frequency adults, but not so far youth. also emergency department attendances hospitalizations some harms. relatively modest date probably reflect restrictions number locations retail outlets constraints commercialization under a continued federal prohibition cannabis. Future evaluations should monitor: sales volumes, prices content tetrahydrocannabinol; prevalence household high school surveys; car crash fatalities injuries involving drivers who are cannabis-impaired; presentations related cannabis; demand treatment disorders; regular vulnerable young people mental health services, schools criminal justice system. Governments propose legalize regulate need fund monitor impacts these policy changes public health, take advantage this develop ways regulating can-nabis minimize health.

Язык: Английский

Процитировано

237

Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets DOI
Samantha Goodman, Elle Wadsworth, Cesar Leos‐Toro

и другие.

International Journal of Drug Policy, Год журнала: 2020, Номер 76, С. 102658 - 102658

Опубликована: Янв. 9, 2020

Язык: Английский

Процитировано

158

Cannabis and its derivatives DOI
Gangotri Debbarma, Pratap Chandra Acharya

Elsevier eBooks, Год журнала: 2024, Номер unknown, С. 37 - 91

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

147

Association of cannabis potency with mental ill health and addiction: a systematic review DOI
Kat Petrilli,

Shelan Ofori,

Lindsey A. Hines

и другие.

The Lancet Psychiatry, Год журнала: 2022, Номер 9(9), С. 736 - 750

Опубликована: Июль 25, 2022

Язык: Английский

Процитировано

133

THC and CBD: Similarities and differences between siblings DOI Creative Commons
Nephi Stella

Neuron, Год журнала: 2023, Номер 111(3), С. 302 - 327

Опубликована: Янв. 12, 2023

Процитировано

59